Lung Cancer
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this roundtable discussion, experts discuss considerations surrounding biospies and biomarkers.
Dr. Jänne reflects on the importance of World Lung Cancer Day, which is marked on August 1 annually.
In the first segment of this multidisciplinary roundtable, experts discuss progress and challenges in lung cancer screening.
The guideline panel additionally determined that guided-bronchoscopy sampling delivers a “superior safety profile."
The researchers explored the role of resilience in mediating the association between stigma and psychosocial adjustment.
The systematic review examined interventions for improving patient function at any stage or phase of lung cancer.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Malignant peritoneal mesothelioma is a rare disease with unspecific abdominal symptoms, often diagnosed at an advanced stage.
The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
The study, which expanded on phase 3 ADAURA, compared treatment with neoadjuvant osimertinib with or without chemotherapy.
Results demonstrated extended median progression-free survival by nearly 9 months versus standard of care.
The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated NSCLC.
The trial compared the combination with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
Latest News
Physician's Weekly
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.